BOSTON (TheStreet) -- Quantitative easing -- the government buying securities to support the economy -- looks more certain by the day. Stocks may rally if so-called QE comes to pass. Investors ought to consider purchasing riskier stocks because they typically would rise more than the broader market. Here are 10 candidates predicted by analysts to double or triple in the next 12 months. They're ordered by their projected return, from big to biggest.
publishes newspapers, including
, operates broadcasting stations and manages Web sites. Second-quarter profit nearly tripled to $195 million, or 73 cents a share, as revenue declined 1.6% to $1.4 billion. The operating margin rose from 15% to 20%. Gannett's stock trades at a trailing earnings multiple of 6, a forward earnings multiple of 5.4, a book value multiple of 1.6 and a cash flow multiple of 3.3 -- 74%, 82%, 58% and 80% discounts to media peer averages. Around 75% of analysts rate the stock "buy" and 25% rank it "hold."
predicts that Gannett's stock will double to $27.
makes semiconductors. Micron swung to a fiscal fourth-quarter profit of $342 million, or 32 cents a share, as revenue surged 91% to $2.5 billion. The operating margin turned positive. Micron's stock sells for a trailing earnings multiple of 3.8, a forward earnings multiple of 6, a book value multiple of 0.9, a sales multiple of 0.8 and a cash flow multiple of 2.3 -- 82%, 54%, 84%, 75% and 84% discounts to semiconductor industry averages. Of analysts following Micron, 14 rate its stock "buy", nine rate it "hold" and just one ranks it "sell."
Raymond James Financial
forecasts that Micron's stock will rise 138% to $18.
sells integrity-management products to semiconductor, fuel-cell and life-sciences companies. It swung to a second-quarter profit of $18 million, or 14 cents a share, from a year-earlier loss. Revenue more than doubled. The operating margin climbed from the negatives to positive 16%. The stock trades at a forward earnings multiple of 6.7, a book value multiple of 1.6 and a cash flow multiple of 9.5 -- 49%, 70% and 36% discounts to industry averages. Five analysts advise purchasing Entegris shares, two recommend holding and one says to sell.
values the stock at $10, suggesting a return of 114%.
develops rockets and space systems for commercial and military customers. Second-quarter profit contracted 27% to $6.4 million, or 11 cents a share, as revenue expanded 25% to $338 million. The operating margin narrowed from 4.8% to 4.1%. Orbital's stock sells for a forward earnings multiple of 13, a book value multiple of 1.6 and a sales multiple of 0.7 -- 12%, 68% and 38% discounts to aerospace and defense industry averages. All eight researchers covering Orbital Sciences advocate purchasing its shares.
FBR Capital Markets
( FBCM) expects Orbital's stock to double to $30.
owns American Airlines. The company's second-quarter loss narrowed 97% to $11 million, or 3 cents a share, as revenue gained 16% to $5.7 billion. The operating margin climbed from negative territory to positive 3.5%. AMR's stock trades at a sales multiple of 0.1 and a cash flow multiple of 2 -- 91% and 59% discounts to airline peer averages. Of analysts following AMR, eight, or 57%, rate its stock "buy", five rate it "hold" and one ranks it "sell." A median price target of $10.06 suggests 60% of upside.
offers a $14 target.
forecasts that AMR's stock will more than triple to $20.
( CLDA) is a biotechnology company. It has several late-stage compounds, including Vilazodone for depression and Stedivaze for cardiac stress. It also sells genetic tests to determine drug response. Its fiscal first-quarter loss narrowed to $14 million, or 51 cents a share, from a loss of $15 million, or 88 cents, a year earlier. Revenue grew 48%. Clinical Data's stock is expensive based on all relative valuation metrics since the company is consistently unprofitable. Still, all six analysts following Clinical Data recommend purchasing its shares.
McNicoll Lewis & Vlak
values the stock at $37, suggesting that it will double.
Gleacher & Co.
is a boutique investment bank. It swung to a second-quarter loss of $5.2 million, or 4 cents a share, from a year-earlier profit. Revenue tumbled 41% to $57 million. The operating margin fell into negative territory. Gleacher's stock trades at a trailing earnings multiple of 7.5, a forward earnings multiple of 6.8, a book value multiple of 0.7 and a sales multiple of 0.7 -- 48%, 59%, 61% and 71% discounts to capital markets peer averages. Two analysts rate it "buy" and three rank it "hold." A median target of $4.17 suggests 132% upside.
predicts that Gleacher's stock will soar 176% to $5.
sells simulation and other software to nuclear power, electric utility and chemical companies. Its second-quarter profit fell 35% to $370,000, or 2 cents a share, as revenue gained 11% to $12 million. The operating margin extended from 6.2% to 7.4%. GSE's stock sells for a forward earnings multiple of 11, a book value multiple of 1.6 and a sales multiple of 1.4 -- 58%, 68% and 93% discounts to software industry averages. All four analysts following GSE advise purchasing its shares. A median target of $8.15 suggests a 141% return in 12 months.
values GSE's stock at $9, implying 172% upside.
acquires, develops and commercializes therapeutics. Avanir's fiscal third-quarter loss expanded 15% to $5.7 million, but the per share loss remained steady at 6 cents due to dilution. Revenue fell 17% to $490,000. The operating margin fell further into negative territory. Avanir has $41 million of cash and no debt. Its stock sells for a book value multiple of 10 and a sales multiple of 79 -- sizable premiums to pharmaceutical industry averages. All four of the analysts evaluating Avanir recommend purchasing its shares.
predicts that Avanir's stock will triple to $10.
is a biopharmaceutical company developing therapies for cancer. It swung to a second-quarter profit of $150,000, or 2 cents a share, from a loss of $4.6 million, or 82 cents, a year earlier. Revenue turned positive. OncoGenex has $48 million of cash and $1.3 million of debt. Its stock trades at a sales multiple of 2.9 and a cash flow multiple of 3.6 -- 97% and 80% discounts to peer averages. All eight researchers covering OncoGenex rate its stock "buy." A median target of $48.17 suggests the stock will more than triple in 12 months.
Rodman & Renshaw
expects the stock to quadruple to $58.
-- Written by Jake Lynch in Boston.
To see these stocks in action, visit the
Become a fan of TheStreet on Facebook.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.